With the general rise in the performance of the third quarterly reports of medical companies, they are still facing severe performance tests

Entering the final period of the third quarter report of 2021, the performance of the medical device industry has gradually surfaced
.
On the whole, most of the companies' revenues in the first three quarters met expectations, and some even achieved very impressive results
.
Among them, it is worth mentioning that Mindray Medical’s performance increase can be said to be very large, and the performance in the first three quarters has exceeded that of the whole year of last year
.
Specifically, on October 19, Mindray Medical’s three quarterly report revealed that the company achieved operating income of 19.
392 billion yuan in the first three quarters, an increase of 20.
72% over the same period of the previous year; net profit attributable to shareholders of listed companies was 6.
663 billion yuan, compared with the previous year.
An increase of 24.
23% over the same period
.
Judging from a single quarter in the third quarter, the company achieved operating income of 6.
613 billion yuan and net profit attributable to shareholders of listed companies of 2.
318 billion yuan, an increase of 20.
25% and 21.
42% respectively over the same period of the previous year
.
It is worth noting that since its listing in October 2018, Mindray Medical's single-quarter net profit growth rate has continued to remain above 20%
.
At the same time as income has increased, Mindray Medical’s expenditure has also risen
.
Among them, in terms of research and development, Mindray Medical has invested nearly 1.
8 billion yuan in research and development in the first three quarters of this year, a year-on-year increase of approximately 19%
.
On October 15th, A-share listed company Intech Medical also issued a three-quarter report performance forecast.
The company expects that its performance will rise sharply from January to September 2021.
The net profit attributable to shareholders of the listed company will be between 6.
779 billion yuan and 6.
979 billion yuan.
A year-on-year increase of 55.
03% to 59.
60%.
The company's industry is medical equipment
.
On October 14, Tongce Medical released a third-quarter report showing that in the first three quarters, the company achieved operating income of 2.
136 billion yuan, a year-on-year increase of 44.
16%; realized a net profit of 620 million yuan, an increase of 55.
09%; Net profit was 608 million yuan, an increase of 56.
69% year-on-year; the three indicators increased by 50.
32%, 55.
12%, and 54.
71% respectively compared to 2019
.
The industry believes that the general increase in the performance of medical companies in the first three quarters is mainly due to the huge challenges that the epidemic has brought to the domestic medical and disease control system, and the country's emphasis on medical investment has been greatly increased; and the overall domestic epidemic situation has remained stable.
, The hospital’s routine diagnosis and treatment activities and the company’s various businesses have gradually returned to normal, due to these two reasons
.
However, it should be noted that as the epidemic continues to be effectively controlled, under the pressure of dual decline in demand and price for epidemic prevention medical devices, the performance of medical device companies is also facing huge challenges
.
Taking Intech Medical as an example, although the company expects its performance in the first three quarters to rise by more than 50% in the same direction, it will achieve a net profit of 6.
779 billion yuan to 6.
979 billion yuan
.
But on the whole, Ingram Medical’s near-term profit has been declining
.
In the first quarter of this year, Intech Medical achieved a net profit of 3.
736 billion yuan.
In the second quarter, its net profit fell to 2.
143 billion yuan, a drop of 43%
.
The estimated profit for the third quarter this time is only about 900 million to 1.
1 billion yuan
.
Ingram Medical is not alone.
In the three-quarter report previously announced by Blue Sail Medical, it is expected to make a profit of 3.
3 billion to 3.
5 billion yuan in the first three quarters, a year-on-year increase of 75% to 85%
.
But it should be noted that Lanfan Medical made a profit of 3.
442 billion yuan in the first half of the year, which means that its third quarter only made a meager profit
.
However, although medical device companies are facing huge challenges, the industry generally believes that domestic medical device companies will still have a lot of room for development
.
Because in the long run, with the intensification of aging, people’s health awareness will continue to increase, consumption levels will upgrade, per capita healthcare consumption expenditures will continue to rise, and policies such as hierarchical diagnosis and treatment, mass procurement, DRGs, and medical device registrant systems will continue to increase.
Implementation, the accelerated pace of domestic substitution of imports, the entire industry will continue to develop at a relatively rapid rate, and the market scale will continue to expand
.
The industry predicts that in the next 5 years, the average annual compound growth rate of the medical device market is about 14%, and it will exceed one trillion by 2023
.